Jun Wei, M.D Ph.D.
Department of Lymphoma - Myeloma, Division of Cancer Medicine
Present Title & Affiliation
Primary Appointment
Assistant Professor, Lymphoma - Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas
Education & Training
Degree-Granting Education
| 2001 | Shanghai Institute of Biochemistry, Chinese Academy of Sciences, Shanghai, CN, Biochemistry and Molecular Biology, Ph.D |
| 1996 | Beijing Medical University, Beijing, CN, MD |
Postgraduate Training
| 2005-2007 | Research Fellowship, Immunology, The University of Texas MD Anderson Cancer Center, Houston, Texas |
| 2002-2005 | Research Fellowship, Cancer Genetics, Baylor college of Medicine, Houston, Texas |
Experience & Service
Faculty Academic Appointments
Assistant Professor, Immunology, The University of Texas MD Anderson Cancer Center, Houston, Texas, 2021 - 2023
Assistant Professor, Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, Texas, 2014 - 2021
Instructor, Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, Texas, 2007 - 2014
Other Professional Positions
Postdoctoral Fellow, The University of Texas MD Anderson Cancer Center, Houston, Texas, 2005 - 2007
Postdoctoral Fellow, Baylor College of Medicine, Houston, Texas, 2002 - 2005
Honors & Awards
| 2020 - 2022 | Institutional Research Grant, MD Anderson Cancer Center |
| 2016 - 2017 | NIH / Brain SPORE Development Research Project, NIH |
| 2013 - 2014 | Melanoma SPORE Career Development Grant, NIH |
| 2012 - 2013 | Brain Cancer SPORE Career Development Award, NIH |
| 2011 - 2012 | Brain SPORE Career Development Program Award, NIH |
Professional Memberships
Selected Presentations & Talks
Regional Presentations
- 2015. Immunotherapeutic miRNAs for Treating Melanoma Brain Metastases. Conference. Melanoma SPORE MDACC, US.
- 2014. The roles of microRNAs on glioma immmune regulation. Conference. Brain Tumor Center UT MDACC, TX, US.
National Presentations
- 2025. First-in-Class Immunomodulatory Anti-Heat Shock Protein 70 (HSP70) Antibody Demonstrates Broad Antitumor Activity Across Myeloma, Lymphoma, and Solid Tumor Models. Conference. ASH. Orlando, Texas, US.
- 2019. Development of an aptamer based immune therapeutics targeting human cancer microenvironment. Invited. Immuno-Oncology Young Investigators' Forum. Houston, TX, US.
- 2016. Mechanisms of therapeutic targeting of osteopontin to reverse immune suppression in GBMs. Conference. Society of Neuro-Oncology. Scottsdale, AZ, US.
- 2013. miR-138 exerts anti-glioma efficacy by targeting immune checkpoints. Conference. 2013 SITC annual meeting. Natinal Harbor, MD, US.
- 2013. MiR-124 Systemically Enhances Anti-tumor Clearance By Inhibiting STAT3 Signaling. Invited. NCI. Birmingham, AL, US.
- 2012. miR-124 systemically enhances anti-tumor clearance by inhibiting STAT3 signaling and reversing glioma-associated immune suppression. Conference. AACR. Miami, FL, US.
- 2010. Glioma Cancer Stem Cells Induce Immune Suppressive Macrophages. Conference. AACR. Miami, FL, US.
- 2009. Cancer stem-like cells from glioblastoma patients mediate immunosuppression that is reversed with STAT-3 blockade. Conference. American Society of Neuro-Oncology. New Orleans, LA, US.
- 2008. Glioma Cancer Stem Cells Mediate Immune Suppression that can be Reversed with p-STAT3 Blockade. Conference. AACR. Miami, FL, US.
Grant & Contract Support
| Date: | 2023 - 2026 |
| Title: | Targeting Heat Shock Protein 70 (HSP70) to Immune Effector Cells to Overcome the Immune Suppressive Myeloma Microenvironment |
| Funding Source: | Leukemia & Lymphoma Society |
| Role: | Co-I |
| ID: | 6684-24 |
| Date: | 2022 - 2027 |
| Title: | Molecular Dissecting and Targeting YAP1 Mediated Cancer Stemness and Immune Suppression in Advanced Gastric Adenocarcinoma |
| Funding Source: | NIH/NCI |
| Role: | Collaborator |
| ID: | 1R01CA269685-01; Project: 00014157 |
| Date: | 2021 - 2023 |
| Title: | Development of an Oligonucleotide-Based Immune Therapeutic Targeting to the Glioblastoma Microenvironment |
| Funding Source: | The University of Texas MD Anderson Cancer Center – Institutional Research Grant (IRG) |
| Role: | PI |
| ID: | RCTS 00057949 & RCTS 00060598; Fund: 123096 |
| Date: | 2020 - 2025 |
| Title: | MODULATION OF THE GLIOBLASTOMA IMMUNE LANDSCAPE WITH STING |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| Date: | 2020 - 2021 |
| Title: | Induction of anti-glioma immunity by CpG ODN targeted silencing of the peptide transporter associated with antigen processing |
| Funding Source: | The Emerson Collective Cancer Research Fund |
| Role: | PI |
| Date: | 2016 - 2020 |
| Title: | Glioblastoma-elaborated osteopontin: role in CNS immune responses and therapeutic target |
| Funding Source: | Ben and Catherine Ivy Foundation |
| Role: | Co-PI |
| Date: | 2016 - 2017 |
| Title: | Development of secreted phosphoprotein 1 -4-1BB bi-specific aptamer targeting GBM specific immune suppression |
| Funding Source: | NIH/NCI |
| Role: | PI |
| Date: | 2016 - 2019 |
| Title: | Nanoparticle targeted STAT3 immune expression |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Co-I |
| ID: | CPRIT IIRA RP160482 |
| Date: | 2015 - 2019 |
| Title: | Therapeutic inhibition of STAT3 in GBM |
| Funding Source: | Ben and Catherine Ivy Foundation |
| Role: | Co-I |
| Date: | 2014 - 2015 |
| Title: | Targeting CMV antigens in GBM patients |
| Funding Source: | Dr. Marnie Rose Foundation |
| Role: | Co-I |
| Date: | 2014 - 2018 |
| Title: | Modulation of microglia and T cell interactions in malignant glioma |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 5R01CA120813 |
| Date: | 2013 - 2014 |
| Title: | MicroRNAs as a novel immunotherapeutic agent for treatment of melanoma metastasis to brain |
| Funding Source: | NIH/NCI UT MD Anderson Cancer Center SPORE in Melanoma |
| Role: | PI |
| ID: | P50 CA093459 |
| Date: | 2013 - 2018 |
| Title: | Targeting malignant gliomas with a novel inhibitor of the STAT3 pathway |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | P50 CA127001 |
| Date: | 2011 - 2013 |
| Title: | Translational center for CNS malignancies targets ependymoma and subependymoma |
| Funding Source: | Dr. David Silverman Foundation |
| Role: | Co-I |
| Date: | 2011 - 2013 |
| Title: | Targeting malignant gliomas with a novel inhibitor of the STAT3 pathway |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | P50 CA127001 |
| Date: | 2010 - 2013 |
| Title: | Targeting malignant gliomas with a novel inhibitor of the STAT3 pathway |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | CA127001-03 |
| Date: | 2010 - 2015 |
| Title: | Effects of a novel phospho-STAT3 inhibitor for treatment of stage IV melanoma patients, including those with CNS metastasis or for treatment of stage IV melanoma |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 2P50CA093459-06A1 |
| Date: | 2010 - 2015 |
| Title: | Effects of a novel phospho-STAT3 inhibitor for treatment of stage IV melanoma patients, including those with CNS metastasis |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 2 P50 CA093459-06 |
| Date: | 2009 - 2012 |
| Title: | Targeting glioma tumorigenesis and immune suppression with p-STAT-3 Blockade, |
| Funding Source: | Cynthia and George Mitchell Foundation |
| Role: | Co-I |
| Date: | 2008 - 2010 |
| Title: | Targeting gliomas with a novel inhibitor of the JAK2/STAT3 pathway |
| Funding Source: | National Brain Tumor Society |
| Role: | Co-I |
| Date: | 2007 - 2008 |
| Title: | De novo Induction of Foxp3+ Regulatory T Cells in Tumor Microenvironment |
| Funding Source: | NIH/NCI |
| Role: | Postdoctoral Fellow |
| ID: | R21-AI073641 |
| Date: | 2000 - 2005 |
| Title: | Molecular dissection of tumor invasion |
| Funding Source: | NIH/NCI |
| Role: | Postdoctoral Fellow |
| ID: | 5-R01-CA087751 |
| Title: | Enhancement of anti-glioblastoma immunity by osetopontin-targeted PD-1 immune checkpoint blockade |
| Funding Source: | The Emerson Collective Cancer Research Fund |
| Role: | PI |
| Title: | Development of oligonucleotide-based immune therapeutic targeting glioblastoma microenvironment |
| Funding Source: | NIH/NINDS |
| Role: | PI |
Selected Publications
Peer-Reviewed Articles
- Lea, ST, Chen, CH, Wei, J, William, I, Lopez Del Castillo, I, Curran, M. NLRP3 Inflammasome Activation Expands the Immunosuppressive Myeloid Stroma and Antagonizes the Therapeutic Benefit of STING Activation in Glioblastoma. Cancer Research Communications 5(6):960-972, 2025. e-Pub 2025. PMID: 40377974.
- Najem, H, Lea, ST, Tripathi, S, Hurley, LA, Chen, CH, William, I, Sooreshjani, M, Bowie, M, Hartley, G, Dussold, C, Pacheco, S, Dmello, C, Lee-Chang, C, McCortney, K, Steffens, A, Walshon, J, Ott, M, Wei, J, Marisetty, AL, Balyasnikova, IV, Stupp, R, Lukas, RV, Hu, J, James, CD, Horbinski, C, Lesniak, MS, Ashley, DM, Priebe, W, Platanias, LC, Curran, M, Heimberger, AB. STING agonist 8803 reprograms the immune microenvironment and increases survival in preclinical models of glioblastoma. Journal of Clinical Investigation 134(12), 2024. e-Pub 2024. PMID: 38941297.
- Groot J, Ott M, Wei J, Kassab C, Fang D, Najem H, O'Brien B, Weathers SP, Matsouka CK, Majd NK, Harrison RA, Fuller GN, Huse JT, Long JP, Sawaya R, Rao G, MacDonald TJ, Priebe W, DeCuypere M, Heimberger AB. A first-in-human Phase I trial of the oral p-STAT3 inhibitor WP1066 in patients with recurrent malignant glioma. CNS Oncol 11(2):CNS87, 2022. e-Pub 2022. PMID: 35575067.
- Wei J, Song R, Sabbagh A, Marisetty A, Shukla N, Fang D, Najem H, Ott M, Long J, Zhai L, Lesniak MS, James CD, Platanias L, Curran M, Heimberger AB. Cell-directed aptamer therapeutic targeting for cancers including those within the central nervous system. Oncoimmunology 11(1):2062827, 2022. e-Pub 2022. PMID: 35433114.
- Sabbagh A, Beccaria K, Ling X, Marisetty A, Ott M, Caruso H, Barton E, Kong LY, Fang D, Latha K, Zhang DY, Wei J, DeGroot J, Curran MA, Rao G, Hu J, Desseaux C, Bouchoux G, Canney M, Carpentier A, Heimberger AB. Opening of the Blood-Brain Barrier Using Low-Intensity Pulsed Ultrasound Enhances Responses to Immunotherapy in Preclinical Glioma Models. Clin Cancer Res 27(15):4325-4337, 2021. e-Pub 2021. PMID: 34031054.
- Shaim H, Shanley M, Basar R, Daher M, Gumin J, Zamler DB, Uprety N, Wang F, Huang Y, Gabrusiewicz K, Miao Q, Dou J, Alsuliman A, Kerbauy LN, Acharya S, Mohanty V, Mendt M, Li S, Lu J, Wei J, Fowlkes NW, Gokdemir E, Ensley EL, Kaplan M, Kassab C, Li L, Ozcan G, Banerjee PP, Shen Y, Gilbert AL, Jones CM, Bdiwi M, Nunez-Cortes AK, Liu E, Yu J, Imahashi N, Muniz-Feliciano L, Li Y, Hu J, Draetta G, Marin D, Yu D, Mielke S, Eyrich M, Champlin RE, Chen K, Lang FF, Shpall EJ, Heimberger AB, Rezvani K. Targeting the αv integrin/TGF-β axis improves natural killer cell function against glioblastoma stem cells. J Clin Invest 131(14), 2021. e-Pub 2021. PMID: 34138753.
- Marisetty A, Wei J, Kong LY, Ott M, Fang D, Sabbagh A, Heimberger AB. MiR-181 Family Modulates Osteopontin in Glioblastoma Multiforme. Cancers (Basel) 12(12), 2020. e-Pub 2020. PMID: 33348707.
- Ott M, Kassab C, Marisetty A, Hashimoto Y, Wei J, Zamler D, Leu JS, Tomaszowski KH, Sabbagh A, Fang D, Gupta P, Priebe W, Zielinski RJ, Burks JK, Long JP, Kong LY, Fuller GN, DeGroot J, Sulman EP, Heimberger AB. Radiation with STAT3 Blockade Triggers Dendritic Cell-T cell Interactions in the Glioma Microenvironment and Therapeutic Efficacy. Clin Cancer Res 26(18):4983-4994, 2020. e-Pub 2020. PMID: 32605912.
- Ott M, Tomaszowski KH, Marisetty A, Kong LY, Wei J, Duna M, Blumberg K, Ji X, Jacobs C, Fuller GN, Langford LA, Huse JT, Long JP, Hu J, Li S, Weinberg JS, Prabhu SS, Sawaya R, Ferguson S, Rao G, Lang FF, Curran MA, Heimberger AB. Profiling of patients with glioma reveals the dominant immunosuppressive axis is refractory to immune function restoration. JCI Insight 5(17), 2020. e-Pub 2020. PMID: 32721947.
- Rao G, Latha K, Ott M, Sabbagh A, Marisetty A, Ling X, Zamler D, Doucette TA, Yang Y, Kong LY, Wei J, Fuller GN, Benavides F, Sonabend AM, Long J, Li S, Curran M, Heimberger AB. Anti-PD-1 Induces M1 Polarization in the Glioma Microenvironment and Exerts Therapeutic Efficacy in the Absence of CD8 Cytotoxic T Cells. Clin Cancer Res 26(17):4699-4712, 2020. e-Pub 2020. PMID: 32554515.
- Dumas AA, Pomella N, Rosser G, Guglielmi L, Vinel C, Millner TO, Rees J, Aley N, Sheer D, Wei J, Marisetty A, Heimberger AB, Bowman RL, Brandner S, Joyce JA, Marino S. Microglia promote glioblastoma via mTOR-mediated immunosuppression of the tumour microenvironment. EMBO J 39(15):e103790, 2020. e-Pub 2020. PMID: 32567735.
- Wei J, Chen P, Gupta P, Ott M, Zamler D, Kassab C, Bhat KP, Curran MA, de Groot JF, Heimberger AB. Immune biology of glioma associated macrophages and microglia: Functional and therapeutic implications. Neuro Oncol 22(2):180-194, 2020. e-Pub 2020. PMID: 31679017.
- Wei J, Marisetty A, Schrand B, Gabrusiewicz K, Hashimoto Y, Ott M, Grami Z, Kong LY, Ling X, Caruso H, Zhou S, Wang YA, Fuller GN, Huse J, Gilboa E, Kang N, Huang X, Verhaak R, Li S, Heimberger AB. Osteopontin mediates glioblastoma-associated macrophage infiltration and is a potential therapeutic target. J Clin Invest 129(1):137-149, 2019. e-Pub 2019. PMID: 30307407.
- Hashimoto Y, Penas-Prado M, Zhou S, Wei J, Khatua S, Hodges TR, Sanai N, Xiu J, Gatalica Z, Kim L, Kesari S, Rao G, Spetzler D, Heimberger A. Rethinking medulloblastoma from a targeted therapeutics perspective. J Neurooncol 139(3):713-720, 2018. e-Pub 2018. PMID: 29869738.
- Gabrusiewicz K, Li X, Wei J, Hashimoto Y, Marisetty AL, Ott M, Wang F, Hawke D, Yu J, Healy LM, Hossain A, Akers JC, Maiti SN, Yamashita S, Shimizu Y, Dunner K, Zal MA, Burks JK, Gumin J, Nwajei F, Rezavanian A, Zhou S, Rao G, Sawaya R, Fuller GN, Huse JT, Antel JP, Li S, Cooper L, Sulman EP, Chen C, Geula C, Kalluri R, Zal T. Glioblastoma stem cell-derived exosomes induce M2 macrophages and PD-L1 expression on human monocytes. Oncoimmunology 4(7). e-Pub 2018. PMID: 29632728.
- Jacobs DI, Liu Y, Gabrusiewicz K, Tsavachidis S, Armstrong GN, Zhou R, Wei J, Ivan C, Calin G, Molinaro AM, Rice T, Bracci PM, Hansen HM, Wiencke JK, Wrensch MR, Heimberger AB, Bondy ML. Germline polymorphisms in myeloid-associated genes are not associated with survival in glioma patients. J Neurooncol 136(1):33-39, 2018. e-Pub 2018. PMID: 28965162.
- Yaghi NK, Wei J, Hashimoto Y, Kong LY, Gabrusiewicz K, Nduom EK, Ling X, Huang N, Zhou S, Kerrigan BC, Levine JM, Fajt VR, Levine G, Porter BF, Marcusson EG, Tachikawa K, Chivukula P, Webb DC, Payne JE, Heimberger AB. Immune modulatory nanoparticle therapeutics for intracerebral glioma. Neuro Oncol. e-Pub 2016. PMID: 27765835.
- Wei J, Nduom EK, Kong LY, Hashimoto Y, Xu S, Gabrusiewicz K, Ling X, Huang N, Qiao W, Zhou S, Ivan C, Fuller GN, Gilbert MR, Overwijk W, Calin GA, Heimberger AB. MiR-138 exerts anti-glioma efficacy by targeting immune checkpoints. Neuro Oncol 18(5):639-48, 2016. e-Pub 2016. PMID: 26658052.
- Kong LY, Wei J, Fuller GN, Schrand B, Gabrusiewicz K, Zhou S, Rao G, Calin G, Gilboa E, Heimberger AB. Tipping a favorable CNS intratumoral immune response using immune stimulation combined with inhibition of tumor-mediated immune suppression. Oncoimmunology 5(5):e1117739, 2016. e-Pub 2016. PMID: 27467917.
- Lin J, Xu K, Wei J, Heimberger AB, Roth JA, Ji L. MicroRNA-124 suppresses tumor cell proliferation and invasion by targeting CD164 signaling pathway in non-small cell lung cancer. J Gene Ther 2(1), 2016. e-Pub 2016. PMID: 27376157.
- Gabrusiewicz K, Rodriguez B, Wei J, Hashimoto Y, Healy LM, Maiti SN, Thomas G, Zhou S, Wang Q, Elakkad A, Liebelt BD, Yaghi NK, Ezhilarasan R, Huang N, Weinberg JS, Prabhu SS, Rao G, Sawaya R, Langford LA, Bruner JM, Fuller GN, Bar-Or A, Li W, Colen RR, Curran MA, Bhat KP, Antel JP, Cooper LJ, Sulman EP, Heimberger AB. Glioblastoma-infiltrated innate immune cells resemble M0 macrophage phenotype. JCI Insight 1(2), 2016. e-Pub 2016. PMID: 26973881.
- Klein SR, Piya S, Lu Z, Xia Y, Alonso MM, White EJ, Wei J, Gomez-Manzano C, Jiang H, Fueyo J. C-Jun N-terminal kinases are required for oncolytic adenovirus-mediated autophagy. Oncogene 34(41):5295-301, 2015. e-Pub 2015. PMID: 25619840.
- Nduom EK, Wei J, Yaghi NK, Huang N, Kong LY, Gabrusiewicz K, Ling X, Zhou S, Ivan C, Chen JQ, Burks JK, Fuller GN, Calin GA, Conrad CA, Creasy C, Ritthipichai K, Radvanyi L, Heimberger AB. PD-L1 expression and prognostic impact in glioblastoma. Neuro Oncol. e-Pub 2015. PMID: 26323609.
- Kong LY, Wei J, Haider AS, Liebelt BD, Ling X, Conrad CA, Fuller GN, Levine NB, Priebe W, Sawaya R, Heimberger AB. Therapeutic targets in subependymoma. J Neuroimmunol 277(1-2):168-175. e-Pub 2014. PMID: 25465288.
- Xu S, Wei J, Wang F, Kong LY, Ling XY, Nduom E, Gabrusiewicz K, Doucette T, Yang Y, Yaghi NK, Fajt V, Levine JM, Qiao W, Li XG, Lang FF, Rao G, Fuller GN, Calin GA, Heimberger AB. Effect of miR-142-3p on the M2 macrophage and therapeutic efficacy against murine glioblastoma. J Natl Cancer Inst 106(8), 2014. e-Pub 2014. PMID: 24974128.
- Doucette T, Rao G, Rao A, Shen L, Aldape K, Wei J, Dziurzynski K, Gilbert M, Heimberger AB. Immune Heterogeneity of Glioblastoma Subtypes: Extrapolation from the Cancer Genome Atlas. Cancer Immunol Res 1(112), 2013. e-Pub 2013. PMID: 24409449.
- Wei J, Wang F, Kong LY, Xu S, Doucette T, Ferguson SD, Yang Y, McEnery K, Jethwa K, Gjyshi O, Qiao W, Levine NB, Lang FF, Rao G, Fuller GN, Calin GA, Heimberger AB. miR-124 inhibits STAT3 signaling to enhance T cell-mediated immune clearance of glioma. Cancer Res 73(13):3913-26, 2013. e-Pub 2013. PMID: 23636127.
- Doucette TA, Kong LY, Yang Y, Ferguson SD, Yang J, Wei J, Qiao W, Fuller GN, Bhat KP, Aldape K, Priebe W, Bögler O, Heimberger AB, Rao G. Signal transducer and activator of transcription 3 promotes angiogenesis and drives malignant progression in glioma. Neuro Oncol 14(9):1136-45, 2012. e-Pub 2012. PMID: 22753228.
- de Groot J, Liang J, Kong LY, Wei J, Piao Y, Fuller G, Qiao W, Heimberger AB. Modulating antiangiogenic resistance by inhibiting the signal transducer and activator of transcription 3 pathway in glioblastoma. Oncotarget 3(9):1036-48, 2012. e-Pub 2012. PMID: 23013619.
- Jethwa K, Wei J, McEnery K, Heimberger AB. miRNA-mediated immune regulation and immunotherapeutic potential in glioblastoma. Clin Investig (Lond) 1(12):1637-1650, 2011. e-Pub 2011. PMID: 22468222.
- Hatiboglu MA, Kong LY, Wei J, Wang Y, McEnery KA, Fuller GN, Qiao W, Davies MA, Priebe W, Heimberger AB. The tumor microenvironment expression of p-STAT3 influences the efficacy of cyclophosphamide with WP1066 in murine melanoma models. Int J Cancer. e-Pub 2011. PMID: 21792892.
- Dziurzynski K, Wei J, Qiao W, Hatiboglu MA, Kong LY, Wu A, Wang Y, Cahill D, Levine NB, Prabhu S, Rao G, Sawaya R, Heimberger AB. Glioma-associated cytomegalovirus mediates subversion of the monocyte lineage to a tumor propagating phenotype. Clin Cancer Res. e-Pub 2011. PMID: 21490182.
- Wei J, Wu A, Kong LY, Wang Y, Fuller G, Fokt I, Melillo G, Priebe W, Heimberger AB. Hypoxia potentiates glioma-mediated immunosuppression. PLoS One 6(1):e16195, 2011. e-Pub 2011. PMID: 21283755.
- Kong LY, Wu AS, Doucette T, Wei J, Priebe W, Fuller GN, Qiao W, Sawaya R, Rao G, Heimberger AB. Intratumoral Mediated Immunosuppression is Prognostic in Genetically Engineered Murine Models of Glioma and Correlates to Immunotherapeutic Responses. Clin Cancer Res 16(23):5722-33, 2010. e-Pub 2010. PMID: 20921210.
- Wu A, Wei J, Kong LY, Wang Y, Priebe W, Qiao W, Sawaya R, Heimberger AB. Glioma cancer stem cells induce immunosuppressive macrophages/microglia. Neuro Oncol 12(11):1113-25, 2010. e-Pub 2010. PMID: 20667896.
- Kong LY, Gelbard A, Wei J, Reina-Ortiz C, Wang Y, Yang EC, Hailemichael Y, Fokt I, Jayakumar A, Qiao W, Fuller GN, Overwijk WW, Priebe W, Heimberger AB. Inhibition of p-STAT3 enhances IFN-alpha efficacy against metastatic melanoma in a murine model. Clin Cancer Res 16(9):2550-61, 2010. e-Pub 2010. PMID: 20388845.
- Wei J, Barr J, Kong LY, Wang Y, Wu A, Sharma AK, Gumin J, Henry V, Colman H, Sawaya R, Lang FF, Heimberger AB. Glioma-associated cancer-initiating cells induce immunosuppression. Clin Cancer Res 16(2):461-73, 2010. e-Pub 2010. PMID: 20068105.
- Wei J, Barr J, Kong LY, Wang Y, Wu A, Sharma AK, Gumin J, Henry V, Colman H, Priebe W, Sawaya R, Lang FF, Heimberger AB. Glioblastoma cancer-initiating cells inhibit T-cell proliferation and effector responses by the signal transducers and activators of transcription 3 pathway. Mol Cancer Ther 9(1):67-78, 2010. e-Pub 2010. PMID: 20053772.
- Kong LY, Wei J, Sharma AK, Barr J, Abou-Ghazal MK, Fokt I, Weinberg J, Rao G, Grimm E, Priebe W, Heimberger AB. A novel phosphorylated STAT3 inhibitor enhances T cell cytotoxicity against melanoma through inhibition of regulatory T cells. Cancer Immunol Immunother 58(7):1023-32, 2009. e-Pub 2009. PMID: 19002459.
- Wei J, DeAngulo G, Sun W, Hussain SF, Vasquez H, Jordan J, Weinberg J, Wolff J, Koshkina N, Heimberger AB. Topotecan enhances immune clearance of gliomas. Cancer Immunol Immunother 58(2):259-70, 2009. e-Pub 2009. PMID: 18594817.
- Humphries W, Wang Y, Qiao W, Reina-Ortiz C, Abou-Ghazal MK, Crutcher LM, Wei J, Kong LY, Sawaya R, Rao G, Weinberg J, Prabhu SS, Fuller GN, Heimberger AB. yuDetecting the percent of peripheral blood mononuclear cells displaying p-STAT-3 in malignant glioma patients. J Transl Med 7:92, 2009. e-Pub 2009. PMID: 19900287.
- Abou-Ghazal M, Yang DS, Qiao W, Reina-Ortiz C, Wei J, Kong LY, Fuller GN, Hiraoka N, Priebe W, Sawaya R, Heimberger AB. The incidence, correlation with tumor-infiltrating inflammation, and prognosis of phosphorylated STAT3 expression in human gliomas. Clin Cancer Res 14(24):8228-35, 2008. e-Pub 2008. PMID: 19088040.
- Kong LY, Abou-Ghazal MK, Wei J, Chakraborty A, Sun W, Qiao W, Fuller GN, Fokt I, Grimm EA, Schmittling RJ, Archer GE, Sampson JH, Priebe W, Heimberger AB. A novel inhibitor of signal transducers and activators of transcription 3 activation is efficacious against established central nervous system melanoma and inhibits regulatory T cells. Clin Cancer Res 14(18):5759-68, 2008. e-Pub 2008. PMID: 18794085.
- Wei J, Duramad O, Perng OA, Reiner SL, Liu YJ, Qin FX. Antagonistic nature of T helper 1/2 developmental programs in opposing peripheral induction of Foxp3+ regulatory T cells. Proc Natl Acad Sci U S A 104(46):18169-74, 2007. e-Pub 2007. PMID: 17978190.
- Hu WG, Wei J, Xia HC, Yang XX, Li F, Li GD, Wang Y, Zhang ZC. Identification of the immunogenic domains in HBsAg preS1 region using overlapping preS1 fragment fusion proteins. World J Gastroenterol 11(14):2088-94, 2005. e-Pub 2005. PMID: 15810073.
- Goode S, Wei J, Kishore S. Novel spatiotemporal patterns of epithelial tumor invasion in Drosophila discs large egg chambers. Dev Dyn 232(3):855-64, 2005. e-Pub 2005. PMID: 15712204.
- Wei J, Hortsch M, Goode S. Neuroglian stabilizes epithelial structure during Drosophila oogenesis. Dev Dyn 230(4):800-8, 2004. e-Pub 2004. PMID: 15254915.
- Hu WG, Wei J, Yang XX, Xia HC, Li F, Zhang ZC. Expression of overlapping PreS1 fragment recombinant proteins for the determination of immunogenic domains in HBsAg PreS1 region. Acta Biochim Biophys Sin (Shanghai) 36(6):397-404, 2004. e-Pub 2004. PMID: 15188054.
- Wei J, Wang YQ, Lu ZM, Li GD, Wang Y, Zhang ZC. Detection of anti-preS1 antibodies for recovery of hepatitis B patients by immunoassay. World J Gastroenterol 8(2):276-81, 2002. e-Pub 2002. PMID: 11925607.
- Wei J, Liu XJ, Wang YQ, Lu ZM, Li GD, Wang Y, Zhang ZC. Development of the diagnostic immunoassay to detect anti-PreS1(21-47aa) antibody--a marker suggesting the health improvement of hepatitis B patients. Clin Chim Acta 317(1-2):159-69, 2002. e-Pub 2002. PMID: 11814471.
- Wei J, Liu XJ, Li GD, Wang Y, Zhang ZC, Wang YQ, Lu ZM. Expression, Purification and Preliminary Clinical Use of Recombinant HBsAg GST-PreS1(21--47 aa) Fusion Proteins. Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao (Shanghai) 33(4):379-385, 2001. e-Pub 2001. PMID: 12040409.
- Yang JY, Jin J, Kong YY, Wei J, Zhang ZC, Li GD, Wang Y, Yuan HY, Li YY. Purification and Characterization of Recombinant Hepatitis B Virus Surface Antigen SS1 Expressed in Pichia pastoris. Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao (Shanghai) 32(5):503-508, 2000. e-Pub 2000. PMID: 12058200.
Invited Articles
- Heimberger AB, Gilbert M, Rao G, Wei J. MicroRNAs as novel immunotherapeutics. Oncoimmunology 2(8):e25124, 2013. e-Pub 2013. PMID: 24083077.
- Wei J, Gabrusiewicz K, Heimberger A. The controversial role of microglia in malignant gliomas. Clin Dev Immunol 2013:285246, 2013. e-Pub 2013. PMID: 23983766.
- Hatiboglu MA, Wei J, Wu AS, Heimberger AB. Immune therapeutic targeting of glioma cancer stem cells. Target Oncol 5(3):217-27, 2010. e-Pub 2010. PMID: 20737294.
Review Articles
- Wei J, Gilboa E, Calin GA, Heimberger AB. Immune Modulatory Short Noncoding RNAs Targeting the Glioblastoma Microenvironment. Front Oncol 11:682129, 2021. e-Pub 2021. PMID: 34532286.
- Humphries W, Wei J, Sampson JH, Heimberger AB. The role of tregs in glioma-mediated immunosuppression: potential target for intervention. Neurosurg Clin N Am 21(1):125-37, 2010. e-Pub 2010. PMID: 19944972.
- Heimberger AB, Kong LY, Abou-Ghazal M, Reina-Ortiz C, Yang DS, Wei J, Qiao W, Schmittling RJ, Archer GE, Sampson JH, Hiraoka N, Priebe W, Fuller GN, Sawaya R. The role of tregs in human glioma patients and their inhibition with a novel STAT-3 inhibitor. Clin Neurosurg 56:98-106, 2009. e-Pub 2009. PMID: 20214040.
Other Articles
- Humphries, W, Wang, Y, Qiao, W, Reina-Ortiz, C, Abou-Ghazal, MK, Crutcher, L, Wei, J, Kong, LY, Sawaya, RE, Rao, G, Weinberg, J, Prabhu, SS, Fuller, GN, Heimberger, AB Correction to. Journal of translational medicine 22(1), 2024. PMID: 38515188.
Abstracts
- L-Y K, Wei J, Gelbard A, Wang YT, Wei Q, Fokt I, Overwijk WW, Priebe W, Heimberger AB. STAT-3 blockade enhances IFN-α immunotherapy for intracerebral malignancy. Neuro-Oncology 11(5):615, 2009. e-Pub 2009.
- Humphries W, Wang Y, Qiao W, Reina-Ortiz, C, Crutcher LM, Wei J, L-Y K, Sawaya R, Rao G, Weinberg J, Prabhu SS, Fuller GN, Heimberger AB. Elevated p-STAT-3 expression in peripheral blood mononuclear cells in glioma patients. Neuro-Oncology 11(5):611, 2009. e-Pub 2009.
- Wei J, Barr J, L-Y K, Yang DS, Sun W, Sharma A, Gumin J, Henry V, Colman H, Priebe W, Sawaya R, Lang FF, Heimberger AB. Cancer stem-like cells from glioblastoma patients mediate immunosuppression that is reversed with STAT-3 blockade. Neuro-Oncology 11(5):616-617, 2009. e-Pub 2009.
- L-Y K, Wei J, Abou-Ghazal MK, Rao G, Priebe W, Heimberger AB. An efficacious therapeutic targeting STAT3 activates cytotoxic T cells through inhibition of regulatory T cells in melanoma brain metastasis patients. Neuro-Oncology 10(5):808, 2008. e-Pub 2008.
- Heimberger AB, Sun W, L-Y K, Abou-Ghazal M, Wei J, Gumin J, Coleman H, Priebe W, Lang FF. Heimberger AB, Sun W, Kong L-Y, Abou-Ghazal M, Wei J, Gumin J, Coleman H, Priebe W, Lang FF. Journal of Clinical Oncology 26(15S), 2008. e-Pub 2008.
- Wei J, Abou-Ghazal M, L-Y K, Gumin J, Colman H, Priebe W, Lang FF, Heimberger AB. Glioma cancer stem cells contribute to immune suppression. Neuro-Oncology 10(5):905, 2008. e-Pub 2008.
- Abou-Ghazal M, Yang DS, Qiao W, Wei J, L-Y K, Fuller GN, Hiraoka N, Priebe W, Sawaya R, Heimberger AB. The incidence of expression, prognostic impact and correlation with the degree of inflammatory response of p-STAT3 in human malignant gliomas. Neuro-Oncology 10(5):866, 2008. e-Pub 2008.
Patient Reviews
CV information above last modified July 22, 2026